Mumbai: Piramal Healthcare has acquired blood plasma products of Germany-based PlasmaSelect AG for an undisclosed amount.
“The company announced the completion of a definitive agreement with PlasmaSelect to acquire its polygeline-based blood plasma products marketed under the brand name ‘Haemaccel´ in over 38 countries,” Piramal Healthcare said in a filing to the Bombay Stock Exchange.
Blood plasma expansion products are infusion pharmaceuticals that help maintain blood plasma volume until blood transfusion can be administered to the patient, in the event of blood loss.
“The acquisition is intended to bring global leadership to Piramal Healthcare’s polygeline-based blood plasma products expansion,” the filing added.
At present, Piramal Healthcare, formerly Nicholas Piramal, markets the products under ‘Haemaccel´ brand name in India and ‘Haemageline´ in 17 other countries.
The annual revenue of Haemaccel and associated brands of Piramal Healthcare and PlasmaSelect together are around Rs62 crore.
Shares of Piramal Healthcare closed at Rs305.80, up 1.58% on the BSE.